SEC Form 4/A · accession 0001144204-18-039106
Arch Therapeutics, Inc. · ARTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Avtar S Dhillon
Director
Period of report
Jul 19, 2018
Accepted (ET)
Jul 20, 2018 · 1:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001537561
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2,F3 | $0.425 | Jul 19, 2018 | A | 220,000 | A | — | Jul 18, 2028 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The Amount or Number of shares of Common Stock listed in Column 7 of the reporting person's original Form 4 was inadvertently listed as "200,000".
- F2The grants reported on this Statement of Changes in Beneficial Ownership on Form 4 were made in connection with that certain letter agreement dated July 19, 2018 by and between the reporting person and Arch Therapeutics, Inc. (the "Company") pursuant to which the reporting person was engaged as an advisor to the Company. The reporting person resigned from his position as a director of the Company effective as of 4:00 PM Eastern Time.
- F3Of the Shares subject to this Grant, 1/12th shall on each of the next twelve (12) monthly anniversaries of the vesting commencement date.